在我们的三级护理中心,据报道,大肠杆菌血液分离株对阿莫西林/克拉维酸的敏感性在2005年超过90%,到2017年逐渐下降至50%.在这项研究中,我们调查了耐药大肠杆菌菌株是否真正增加,或者报告的敏感性明显下降是否归因于2014年EUCAST指南对CLSI的替代.我们从1985年到2018年随机选择了237种大肠杆菌血液分离物(储存在-80°C),并重新评估了它们的MIC值。同时应用CLSI(克拉维酸的固定比例)和EUCAST指南(克拉维酸的固定浓度)。并行,通过圆盘扩散重新测试了这些分离株的敏感性,根据EUCAST指南。对237个分离株中的233个成功进行了全基因组测序。在237个分离株中只有130个(55.0%),根据EUCAST和CLSI标准进行的测试对阿莫西林/克拉维酸的MIC值相同.在237个分离株中的64个(27.0%),MIC值偏离了一个稀释度;在38(16.0%)中,两次稀释;五次(2.1%),三次稀释。从这107个不一致的结果中,根据EUCAST方法进行的测试显示,在93个大肠杆菌菌株中(94.1%)具有更多的抗性。此外,与CLSI测试程序相比,根据EUCAST指南进行的表型敏感性测试倾向于与β-内酰胺酶基因的存在更好地相关.这项研究强调了在进行阿莫西林/克拉维酸的MIC测试时,EUCAST和CLSI方法之间的低一致性。当应用EUCAST指南时,更多菌株被归类为抗性。EUCAST和CLSI之间的低一致性得到了WGS的证实,因为大多数EUCAST抗性/CLSI敏感分离株都含有β-内酰胺酶基因。
In our tertiary care center, the reported susceptibility of E. coli blood isolates to amoxicillin/clavulanic acid exceeded 90% in 2005 and showed a progressive decrease to 50% by 2017. In this study, we investigate whether there is a real increase in resistant E. coli strains or if this apparent decline in reported susceptibility might be attributed to the substitution of CLSI by EUCAST
guidelines in 2014. We randomly selected 237 E. coli blood isolates (stored at - 80 °C) from 1985 to 2018 and reassessed their MIC values, applying both the CLSI (fixed ratio of clavulanic acid) and EUCAST
guidelines (fixed concentration of clavulanic acid). In parallel, the susceptibility of these isolates was retested by disk diffusion, according to the EUCAST
guidelines. Whole genome sequencing was successfully performed on 233 of the 237 isolates. In only 130 of the 237 isolates (55.0%), testing according to the EUCAST and CLSI criteria delivered identical MIC values for amoxicillin/clavulanic acid. In 64 of the 237 isolates (27.0%), the MIC values diverged one dilution; in 38 (16.0%), two dilutions; and in five (2.1%), three dilutions. From these 107 discrepant results, testing according to EUCAST methodology revealed more resistant profiles in 93 E. coli strains (94.1%). Also, phenotypical susceptibility testing according to EUCAST
guidelines tends to correlate better with the presence of beta-lactamase genes compared to CLSI testing procedure. This study highlights the low agreement between EUCAST and CLSI methodologies when performing MIC testing of amoxicillin/clavulanic acid. More strains are categorized as resistant when EUCAST
guidelines are applied. The low agreement between EUCAST and CLSI was confirmed by WGS, since most of EUCAST resistant/CLSI sensitive isolates harbored beta-lactamase genes.